Completed PHASE2 NCT00049530

PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor

Sponsor: Eastern Cooperative Oncology Group

Conditions Melanoma (Skin)

Interventions PEG-interferon alfa-2b

Updated 7 times since 2017 Last updated: Jun 14, 2023 Started: Jan 13, 2004 Primary completion: Aug 31, 2012 Completion: Jun 30, 2014

This PHASE2 trial investigates Melanoma (Skin) and is currently completed. Eastern Cooperative Oncology Group leads this study, which shows 7 recorded versions since 2004 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jul 2023 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2023 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jan 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Data source: Eastern Cooperative Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Birmingham, United States , Bloomington, United States , Canton, United States , Carthage, United States , Charleston, United States , Cleveland, United States , Decatur, United States , Eureka, United States , Galesburg, United States and 14 more locations